RxDoctor Payments Data

Michael Diringer

Critical Care Medicine · Saint Louis, MONPI 1881625390

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,900 of the $2,487 with a category attached, or 76.4%. Pfizer accounts for 76.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $1,970 and has fallen 95.4% since, to $91 in 2021.

$2,487in general payments, 2019–2025

Across 4 payments — averaging $621.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • AstraZeneca$427
  • ZOLL Circulation Inc$91
  • Bard Access Systems, Inc.$70
$525,023in research payments, 2019–2025

Across 15 payments — averaging $35,002 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • C. R. Bard, Inc. & Subsidiaries$498K
  • Biogen$24K
  • Bard Peripheral Vascular, Inc.$4K

What the payments were for

  • Consulting fees$42717%
  • Speaking & faculty fees$1,90076%
  • Food & beverage$1616%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,487 in reported general payments places this provider in the 85th percentile of 208 critical care medicine providers in Missouri.

See all critical care medicine providers in Missouri

Other critical care medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →